Cullinan Therapeutics
CGEM
14.90
-0.73
-4.67%
Cullinan Therapeutics
US · CGEM
#3243 by market cap
Listed 2021
14.90
-0.73
-4.67%
Live - 5344 symbols - heartbeat 258s ago
· 2026-10-08 10:00
Pre-market
15.60
-0.19%
After-hours
15.63
0.00%
- Market cap
- 958.88M
- P/E (TTM)i
- -4.79
- P/Bi
- 2.98
- EPSi
- -3.36
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on CGEM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.6 percentage points.
Institutional ownership
- Held by institutions
- 112.34% -1.63pp
- Institutions
- 220 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund54.57%
Hedge Fund27.05%
VC/PE Fund24.38%
Public Company3.74%
Individual/Insider1.22%
Family Office/Trust0.97%
Insurance Company0.72%
Private Company0.71%
Government Pension Fund0.19%
Top holders as of 2026-06-30
MPM BioImpact LLC
15.12% · 9.73M sh
Lynx1 Capital Management LP
13.93% · 8.96M sh
BVF Partners L.P.
8.94% · 5.75M sh
BlackRock
8.13% · 5.23M sh
T. Rowe Price Group, Inc.
5.95% · 3.83M sh
State Street Global Advisors
5.70% · 3.67M sh
Kynam Capital Management, LP
4.84% · 3.11M sh
Vanguard Capital Management, LLC
4.63% · 2.98M sh
RTW Investments, LP
3.67% · 2.36M sh
Artal Group S.A.
2.94% · 1.89M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 31 sells
| Name | Role | Stake |
|---|---|---|
| Lynx1 Capital Management LP | -- | 13.93% |
| Jennifer Michaelson | Chief Scientific Officer | 0.25% |
| Corinne Savill | Chief Business Officer | 0.24% |
| Nadim Ahmed | Chief Executive Officer | 0.21% |
| Mary Fenton | Chief Financial Officer | 0.20% |
| Jeffrey Jones | Chief Medical Officer | 0.10% |
| Jacquelyn Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0.09% |
| Anthony Rosenberg | Independent Chairperson | 0.07% |
| Jeffrey Trigilio | Chief Financial Officer | 0.07% |
| Stephen Webster | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Jennifer Michaelson | Chief Scientific Officer | Automatic Disposition | -4,000 | $21.57 |
| 2026-09-07 | Jennifer Michaelson | Chief Scientific Officer | Derivative Exercise and Sale | -4,000 | $4.30–21.57 |
| 2026-08-12 | Jennifer Michaelson | Chief Scientific Officer | Derivative Exercise and Sale | -30,000 | $4.30–20.26 |
| 2026-07-05 | Jennifer Michaelson | Chief Scientific Officer | Automatic Disposition | -4,000 | $17.82 |
| 2026-07-05 | Jennifer Michaelson | Chief Scientific Officer | Derivative Exercise and Sale | -4,000 | $4.30–17.82 |
| 2026-06-29 | Mary Fenton | Chief Financial Officer | Other Acquisition | +1,541 | $8.60 |
| 2026-06-29 | Jacquelyn Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | Other Acquisition | +2,470 | $8.60 |
| 2026-06-15 | Stephen Webster | Independent Director | Other Derivative Acquisition | +25,319 | $13.55 |
| 2026-06-15 | Anthony Rosenberg | Independent Chairperson | Other Derivative Acquisition | +25,319 | $13.55 |
| 2026-06-15 | Mary Thistle | Director | Other Derivative Acquisition | +25,319 | $13.55 |
| 2026-06-15 | Andrew Allen | Director | Other Derivative Acquisition | +21,781 | $13.55 |
| 2026-06-15 | David Meek | Independent Director | Other Derivative Acquisition | +25,319 | $13.55 |
| 2026-06-15 | Mittie Doyle | Director | Other Derivative Acquisition | +21,781 | $13.55 |
| 2026-05-04 | Jennifer Michaelson | Chief Scientific Officer | Automatic Disposition | -4,000 | $14.60–15.58 |
| 2026-05-04 | Jennifer Michaelson | Chief Scientific Officer | Derivative Exercise and Sale | -4,000 | $4.30–14.60 |
| 2026-03-04 | Jennifer Michaelson | Chief Scientific Officer | Automatic Disposition | -4,000 | $15.68 |
| 2026-03-04 | Jennifer Michaelson | Chief Scientific Officer | Derivative Exercise and Sale | -4,000 | $4.30–15.68 |
| 2026-02-24 | Jennifer Michaelson | Chief Scientific Officer | Automatic Disposition | -1,780 | $14.14 |
| 2026-02-23 | Jeffrey Jones | Chief Medical Officer | Open Market Disposition | -4,582 | $14.47 |
| 2026-02-23 | Nadim Ahmed | Chief Executive Officer | Open Market Disposition | -13,515 | $14.47 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:09 · For reference only, not investment advice and not tailored to your situation.